초록 ▼

The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the m

The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal epithelium, the effect on the standing potential or the effect on the proteoglycanes of the scleral tissue of the eye, by way of EOG examination, by way on the size of the so-called c-wave in ERG-recordings, or by the state of the Ca2+-channels or on the [3H]-ryanodine receptors of the retinal pigment epithelium.

대표청구항 ▼

The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the m

The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal epithelium, the effect on the standing potential or the effect on the proteoglycanes of the scleral tissue of the eye, by way of EOG examination, by way on the size of the so-called c-wave in ERG-recordings, or by the state of the Ca2+-channels or on the [3H]-ryanodine receptors of the retinal pigment epithelium. Lin, H., et al., "Expression of Recombinant Genes in Myocardium In Vivo After Direct Injection of DNA," Circulation 82:2217-2221 (1990). Loyter et al., Exp. Cell Res. 139:223-234 (1982). Magee et al. ,Cancer Res. 38:1173-1176 (1978). Malone et al., Proc. Natl. Acad. Sci. USA 86:6077-6081 (Aug. 1989). Mandi, C.W., et al., " In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model," Nat. Med. 4:1438-1440 (Dec. 1998). Mannino et al., Biotechniques 6:682-690 (Jun.-Aug. 1988). McCrae et al., Eur. J. Biochem. 116:467-470 (1981). Mosier et al., Nature 335:256-259 (Sep. 1988). Muesing et al., Cell 48:691 (1987). Mullner et al., Cell 53:815-825 (Jun. 1988). Nakatani et al., Biotechnology 7:805-810 (1989). Namikawa et al., Science 242:1684-1686 (Dec. 1988). New England Biolabs 1986/87 Catalog, 32 Tozer Rd., Beverly, MA 01915-0990 USA, p. 45. Nicolau et al., Proc. Natl. Acad. Sci. USA 80:1068-1072 (1983). Nicolau, C., et al., "Liposomes as Carriers for in Vivo Gene Transfer and Expression," Meth. Enzymol. 149:157-176 (1987). Norton et al., Mol. Cell Biol. 5:281